Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official journal of the American College of Chest Physicians, has published results from the Phase 3 ENHANCE-CHINA trial evaluating Ohtuvayre® (ensifentrine) in chronic obstructive pulmonary disease...
ACT Genomics Upgrades Clinically Recognized Genomic Test to 101-Gene Panel with 7-Day Turnaround
TAIPEI, April 20, 2026 /PRNewswire/ -- ACT Genomics today announced a significant upgrade to the ACTDrug® series, its next-generation sequencing (NGS) genomic profiling service. The updated panel now covers 101 clinically relevant genes and offers a seven-working-day turnaround time, designed to provide comprehensive genomic information to support physicians in making treatment decision for newly diagnosed patients with advanced or...
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
SUZHOU, China, April 20, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the latest preclinical data for three proprietary pipeline assets at the American Association for Cancer Research (AACR) Annual Meeting (from...
Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round
NEW YORK, April 20, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners,...
Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
• The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure VALBY, Denmark, April 20, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today presented new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026...
BREAKTHROUGH PRIZE ANNOUNCES 2026 LAUREATES
Six $3 Million Prizes Awarded for Outstanding Discoveries in Life Sciences, Fundamental Physics and Mathematics Gene Therapies for Inherited Blindness, Sickle Cell Disease and Beta-Thalassemia Discovery of Key Genetic Cause of ALS and Frontotemporal Dementia Precision Measurement of Muon's Magnetic Moment Advances in Mathematics of Waves and Nonlinear Systems Special Prize...
Ddrops® Supports Children’s Healthy Growth at Dripping Colours Montessori Sports Day — Every Step Toward a Healthier Future
KUALA LUMPUR, Malaysia, April 18, 2026 /PRNewswire/ -- Ddrops® participated in the annual Sports Day hosted by Dripping Colours Montessori on April 18, 2026, reinforcing its commitment to supporting children's healthy growth through active lifestyles and proper nutrition. Ddrops® x Dripping Colours Montessori Sports Day Serving children aged 2 to 6, Dripping Colours Montessori integrates Montessori principles that...
Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it has released present results from three...
ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
MUNICH, April 18, 2026 /PRNewswire/ -- The largest real-world study of its kind, presented today at ESCMID Global 2026, shows that maternal vaccination against respiratory syncytial virus (RSV) reduces the risk of hospitalisation in young infants by over 80% when given at least two weeks before birth. RSV is a common virus that can cause severe respiratory illness in infants...
Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better support treatment decision-making. SEOUL, South Korea, April 18, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for...
